GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Cyclically Adjusted Revenue per Share

Cellectis (XPAR:ALCLS) Cyclically Adjusted Revenue per Share : €0.71 (As of Mar. 2025)


View and export this data going back to 2007. Start your Free Trial

What is Cellectis Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cellectis's adjusted revenue per share for the three months ended in Mar. 2025 was €0.098. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.71 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Cellectis's average Cyclically Adjusted Revenue Growth Rate was -4.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cellectis was -4.60% per year. The lowest was -4.60% per year. And the median was -4.60% per year.

As of today (2025-05-29), Cellectis's current stock price is €1.358. Cellectis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €0.71. Cellectis's Cyclically Adjusted PS Ratio of today is 1.91.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cellectis was 12.13. The lowest was 1.18. And the median was 2.94.


Cellectis Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Cellectis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Cyclically Adjusted Revenue per Share Chart

Cellectis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.83 0.81 0.75 0.72

Cellectis Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.74 0.73 0.72 0.71

Competitive Comparison of Cellectis's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted PS Ratio falls into.


;
;

Cellectis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cellectis's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.098/120.3800*120.3800
=0.098

Current CPI (Mar. 2025) = 120.3800.

Cellectis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.208 100.440 0.249
201509 0.215 99.950 0.259
201512 0.773 100.040 0.930
201603 0.200 100.020 0.241
201606 0.442 100.630 0.529
201609 0.281 100.340 0.337
201612 0.218 100.650 0.261
201703 0.178 101.170 0.212
201706 0.163 101.320 0.194
201709 0.143 101.330 0.170
201712 0.136 101.850 0.161
201803 0.136 102.750 0.159
201806 0.102 103.370 0.119
201809 0.018 103.560 0.021
201812 0.018 103.470 0.021
201903 0.022 103.890 0.025
201906 0.024 104.580 0.028
201909 0.182 104.500 0.210
201912 0.094 104.980 0.108
202003 1.068 104.590 1.229
202006 0.061 104.790 0.070
202009 0.123 104.550 0.142
202012 -0.173 104.960 -0.198
202103 0.502 105.750 0.571
202106 0.204 106.340 0.231
202109 0.155 106.810 0.175
202112 -0.287 107.850 -0.320
202203 0.033 110.490 0.036
202206 0.027 112.550 0.029
202209 0.004 112.740 0.004
202212 0.331 114.160 0.349
202303 0.003 116.790 0.003
202306 0.003 117.650 0.003
202309 0.003 118.260 0.003
202312 0.004 118.390 0.004
202403 0.040 119.470 0.040
202406 0.083 120.200 0.083
202409 0.146 119.560 0.147
202412 0.121 119.950 0.121
202503 0.098 120.380 0.098

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Cellectis  (XPAR:ALCLS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cellectis's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.358/0.71
=1.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cellectis was 12.13. The lowest was 1.18. And the median was 2.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cellectis Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Cellectis's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines